Moderna (NASDAQ: MRNA), alongside Novavax, is running at full speed in the vaccine race. The Trump Administration’s recent agreement with Moderna to order 100 million doses adds to the argument that MRNA is at the front of the pack. While the announcement is a positive catalyst, investors are doubtful that we will see an enormous rally.… Read more
MRNA’s key COVID-19 developments so far
- US government is willing to fund mRNA-173 through every trial until regulatory approval.
- Biomedical Advanced Research and Development Authority (BARDA) is ready to give Moderna (NASDAQ: MRNA) $483 million to expedite mRNA-173 through clinical development.
- Lonza Group, via its agreement with Moderna, is manufacturing mRNA-173 at their US and Switzerland operations.